Improved cardiac transplant survival with thyroxine treatment of hemodynamically unstable donors: 95.2% graft survival at 6 and 30 months.
Orlowski
J P
JP
Colorado Organ Recovery Systems, University of Colorado Health Sciences Center, Denver 80209.
Spees
E K
EK
D000206:Actuarial Analysis; D000328:Adult; D004280:Dobutamine / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology*; D016027:Heart Transplantation / Q000502:physiology*; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D016019:Survival Analysis; D013974:Thyroxine / Q000627:therapeutic use*; D013997:Time Factors; D014019:Tissue Donors
D004280:Dobutamine; D013974:Thyroxine; D004298:Dopamine